Trial Profile
A Double-blind, Randomised, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAD and MAD of CORT125281 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Exicorilant (Primary) ; Pioglitazone; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Corcept Therapeutics
- 24 Jul 2018 Status changed from recruiting to completed.
- 13 Nov 2017 New trial record